Blue Cloud Softech Solutions Ltd (BLUECLOUDS)

Information Technology · IT - Software · NSE · Updated 1 September 2026
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
₹20.21 ↓ 31.91% (1Y)

🎯 Key Takeaways

  • Blue Cloud Softech Solutions Ltd is transitioning from a niche IT software player into a broader technology and healthcare innovation platform, marked by strategic partnerships in preventive healthcare and increasing institutional interest. The company maintains strong profitability metrics (ROE 52.
  • Revenue grew 5.4% QoQ to ₹293 in Q1FY27.
  • ⚠️ 1) Revenue stagnation and margin volatility across quarters raise concerns about scalability of new initiatives. 2) Reliance on a single partnership (
Market Cap
₹1,522
P/E Ratio
18.2
P/B Ratio
12.48
ROE
52.6%
ROCE
51.0%
Debt/Equity
0.74
Promoter
38.4%

📖 The Story

Blue Cloud Softech Solutions Ltd is transitioning from a niche IT software player into a broader technology and healthcare innovation platform, marked by strategic partnerships in preventive healthcare and increasing institutional interest. The company maintains strong profitability metrics (ROE 52.6%, ROCE 51.0%) but faces revenue stagnation and margin pressure, with a 1Y return of -31.91%. It is in an early-stage transformation phase, leveraging its AI-driven health platform to expand into community wellness, though financial results show limited growth and operational volatility.

📰 What's Happening

In August 2026, the company announced a technology partnership with the Mahesh Babu Foundation to launch GMB Life, a preventive wellness app built on its BluHealth platform, marking its first major push into community healthcare. This follows a board meeting scheduled for September 1, 2026, to approve the 35th AGM notice and appoint a scrutinizer for remote e-voting, potentially setting the stage for future capital actions. Management views this as part of a broader strategy to expand its AI-driven health platform into preventive care, signaling a strategic pivot beyond traditional software services.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

MetricJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue206253265278293
Operating Profit2022292728
OPM %9.6%8.9%11.1%9.8%9.7%
Net Profit1415191218
EPS₹0.33₹0.35₹0.37₹0.16₹0.23

Quarterly revenue has plateaued over the past year, growing from ₹206 lakh in June 2025 to ₹293 lakh in June 2026, but with significant volatility and no consistent upward trend. Operating margins have remained relatively stable around 9-11%, though they dipped to 8.9% in September 2025 before recovering slightly. Net profit and EPS peaked in December 2025 (₹19 lakh, ₹0.37) but declined in the most recent quarters, indicating earnings pressure despite revenue gains. The lack of sustained revenue growth and margin compression suggests operational challenges in scaling the new healthcare initiatives.

🔮 Management Outlook & What's Next

Management has not provided formal forward guidance on revenue or profitability in the latest filings, but the launch of GMB Life and the partnership with Mahesh Babu Foundation indicate intent to expand in the health tech segment. The upcoming AGM and board meeting may offer clarity on capital allocation plans and strategic timelines for the wellness initiative. Until then, management’s outlook remains implied through strategic moves rather than explicit guidance.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

ItemMar 2025Mar 2025Mar 2026Mar 2026
Equity Capital44444475
Reserves5578114848
Borrowings659087269
Total Liabilities4353513411,367
Fixed Assets365868
Investments0000
Total Assets4353513411,367

The balance sheet shows a significant increase in equity and reserves from March 2025 (₹122 crore total) to March 2026 (₹159 crore), driven by retained earnings and possibly capital infusions, while borrowings remain low and stable at ₹269 lakh. Total assets grew from ₹351 crore to ₹1,367 crore, reflecting asset expansion likely tied to investments in health tech infrastructure. The strong equity base and minimal debt suggest a conservative capital structure, supporting long-term investment in strategic initiatives without high financial risk.

💰 Cash Flow Statement (₹ Cr)

ItemMar 2025
Operating-13
Investing-11
Financing+20
Net Cash Flow-4

👥 Shareholding Pattern

CategoryQ2FY26Q3FY26Q4FY26Q1FY27
Promoters38.6%38.5%38.4%38.4%
FII13.3%13.3%13.3%13.3%
DII0.0%0.0%0.0%0.0%
Public12.3%12.6%13.2%14.4%
# Shareholders58,41859,21361,54610,00,95,123

Institutional holding by FIIs has remained steady around 13.28-13.29% over the past year, with no significant changes in DII or public shareholding trends. The promoter holding is stable at 38.44%, and the number of shareholders has gradually increased from 58,418 to 10,00,95,123, indicating growing retail interest. There are no signs of institutional selling or accumulation spikes, suggesting neutral investor sentiment with gradual engagement.

⚖️ Peer Comparison — IT - Software

Company MCap (₹ Cr) P/E ROCE ROE D/E
TCS 8.48 L Cr 17.0 63.2% 46.7% 0.00
INFY 4.64 L Cr 15.4 44.9% 32.7% 0.00
HCLTECH 3.57 L Cr 20.4 31.6% 23.2% 0.00
WIPRO 1.79 L Cr 14.3 18.1% 15.1% 0.19
TECHM 1.60 L Cr 28.2 24.8% 17.4% 0.00
LTM 1.39 L Cr 26.5 30.5% 21.6% 0.00
OFSS 1.06 L Cr 31.1 60.3% 43.6% 0.00
PERSISTENT 92,307 47.5 32.7% 24.5% 0.00
COFORGE 89,069 40.9 25.6% 20.7% 0.04
MPHASIS 46,816 24.5 22.3% 17.8% 0.17

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) Revenue stagnation and margin volatility across quarters raise concerns about scalability of new initiatives. 2) Reliance on a single partnership (Mahesh Babu Foundation) for healthcare expansion introduces execution and market adoption risk. 3) No formal forward guidance from management creates uncertainty around timelines for profitability or growth in the health tech segment. 4) Despite strong ROE and ROCE, the company's core software business shows signs of plateauing, with limited evidence of new customer acquisition or product-led growth.

🧠 Analyst's Read

Blue Cloud Softech is repositioning its business around AI-driven health technology, but financial performance and operational consistency remain constrained. The success of GMB Life and future capital actions will be critical catalysts to watch, as current metrics do not yet reflect meaningful growth or margin expansion to justify a turnaround.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when BLUECLOUDS files new disclosures

Track BLUECLOUDS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track BLUECLOUDS — Free

Free account · 2 AI queries/day